title: HER4 selectively coregulates estrogen stimulated genes associated with breast tumor cell proliferation.
abstract: The EGFR-family member HER4 undergoes regulated intramembrane proteolysis (RIP) to generate an intracellular domain (4ICD) that functions as a transcriptional coactivator. Accordingly, 4ICD coactivates the estrogen receptor (ER) and associates with ER at target gene promoters in breast tumor cells. However, the extent of 4ICD coactivation of ER and the functional significance of the 4ICD/ER transcriptional complex is unclear. To identify 4ICD coactivated genes we performed a microarray gene expression analysis of β-estradiol treated cells comparing control MCF-7 breast cancer cells to MCF-7 cells where HER4 expression was stably suppressed using a shRNA. In the MCF-7 cell line, β-estradiol significantly stimulated or repressed by 2-fold or more 726 or 53 genes, respectively. Significantly, HER4/4ICD was an obligate coactivator for 277 or 38% of the β-estradiol stimulated genes. Ingenuity Pathway Analysis of β-estradiol regulated genes identified significant associations with multiple cellular functions regulating cellular growth and proliferation, cell cycle progression, cancer metastasis, decreased hypoplasia, tumor cell migration, apoptotic resistance of tumor cells, and increased transcription. Genes coactivated by 4ICD displayed functional specificity by only significantly contributing to cellular growth and proliferation, cell cycle progression, and decreased hypoplasia. In direct concordance with these in situ results we show that HER4 knockdown in MCF-7 cells results in a loss of estrogen stimulated tumor cell proliferation and cell cycle progression, whereas, estrogen stimulated tumor cell migration was unaffected by loss of HER4 expression. In summary, we demonstrate for the first time that a cell surface receptor functions as an obligate ER coactivator with functional specificity associated with breast tumor cell proliferation and cell cycle progression. Nearly 90% of ER positive tumors coexpress HER4, therefore we predict that the majority of breast cancer patients would benefit from a strategy to therapeutic disengage ER/4ICD coregulated tumor cell proliferation.
authors: Department of Cell and Molecular Biology, Tulane University, New Orleans, LA 70118, USA.
authors: Wen
authors: W
authors: Han
authors: Department of Cell and Molecular Biology, Tulane University, New Orleans, LA 70118, USA. Electronic address: fjones3@tulane.edu.
authors: Frank E
authors: FE
authors: Jones
mesh_terms: D001943:Breast Neoplasms / Q000378:metabolism*; D049109:Cell Proliferation; D066246:ErbB Receptors / Q000378:metabolism*; D004967:Estrogens / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D061986:MCF-7 Cells; D066247:Receptor, ErbB-4
chemical_list: D004967:Estrogens; C587689:ERBB4 protein, human; D066246:ErbB Receptors; D066247:Receptor, ErbB-4
keywords: 4ICD; BSA; Breast cancer; CS-FBS; Cell cycle; Cy3; Cy5; EGFR; EGFR-family; ER; Gene regulation; HER4 intracellular domain; IPA; Ingenuity Pathway Analysis; PgR; RIP; SE; SRC; Steroid receptors; bovine serum albumin; cDNA; cRNA; charcoal stripped fetal bovine serum; complementary DNA; complementary RNA; cyanine 3; cyanine 5; epidermal growth factor receptor; estrogen receptor alpha; p160 steroid receptor coactivator; progesterone receptor; regulated intramembrane proteolysis; standard error